Chassieu (France), 19 March 2026 – 8:45 am - Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that its next Ordinary and Extraordinary General Meeting will be held on 3 April 2026.

Amoéba shareholders are invited to attend the Ordinary and Extraordinary General Meeting to be held on Friday 3 April 2026, at 9.00 am, at the Company's registered office at 38 avenue des Frères Montgolfier, Chassieu (69680, France).

The notice of meeting, including the agenda and draft resolutions, was published in the BALO (“Bulletin des Annonces Légales Obligatoires”) on 18 March 2026.

The documents and information required in particular by Articles R. 22-10-23, L. 225-115 and R. 225-83 of the French Commercial Code are made available to shareholders from the date of the notice convening the Meeting, in accordance with the applicable regulatory provisions, and are published on the Company's website at:

https://amoeba-nature.com/en/investor/general-assembly/

For information, electronic voting via the secure VOTACCESS voting platform for the General Meeting of 3 April 2026 will be open from Wednesday 18 March 2026 at 12:00 (Paris time) until the day before the Meeting, i.e. Thursday 2 April 2026 at 15:00 (Paris time). Shareholders wishing to use this platform may consult the access procedures in the notice of meeting and on the company's website.

About Amoéba:

Founded in 2010, Amoéba is a green tech company based in Chassieu (Lyon, France) that aims to become a major player in microbiological risk treatment through the patented use of amoebae in the plant protection and cosmetics sectors.

With unique expertise protected by numerous patents, Amoéba is currently the only company authorised to use the Willaertia amoeba industrially for biocontrol and cosmetic applications. To the Company's knowledge, it is also the only company capable of producing it on an industrial scale in volumes compatible with commercial applications, in order to offer a viable alternative to the chemical products widely used today.

Amoéba is currently focusing on the global biocontrol market for plant protection and the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory approvals, the Company has taken the necessary regulatory steps and submitted applications for approval in Europe and the United States. The active substance has already been approved in the United States in 2022 and received a positive and final report from the EFSA in Europe. Product registration was obtained in 2025 for the United States and is expected in 2026 in France and then in other targeted European countries.

The cosmetic application does not require prior approval from a competent authority in Europe or the United States. The cosmetic ingredient is already listed on the INCI (International Nomenclature of Cosmetic Ingredients) list, paving the way for its commercialisation worldwide, except in China, where local approval is required.

Amoéba is listed on Euronext Growth (ALMIB). The company is a member of the Bpifrance Excellence network and is eligible for the PEA-PME scheme. For more information, visit www.amoeba-nature.com.

Contacts:

Disclaimer

This press release contains certain forward-looking statements concerning Amoéba which are based on its own assumptions and estimates and on information that is currently available to us. However, Amoéba gives no assurance that the estimates contained in such forward-looking statements will be verified, with these estimates subject to numerous risks, including the risks set forth in Amoéba's universal registration document filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on March 18, 2026 under number D.26-0108 and available on the Amoéba website (www.amoeba-nature.com). The forward-looking statements contained in this press release are also subject to risks not yet known to Amoéba or not currently considered material by Amoéba . The occurrence of all or part of such risks could cause Amoéba's actual results, financial conditions, performance, or achievements to be materially different from such forward-looking statements.